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Stroke is a devastating event for patients and their families. Paradoxical embolism through a patent foramen ovale (PFO) is a recognized cause of
stroke. Percutaneous PFO closure is a simple and safe procedure. The debate on PFO closure is far from settled. This is, in part, due to the fact
that the three published randomized controlled trials (RCTs) on PFO closure vs. medical therapy were negative regarding their primary end-
point; however, as-treated and per-protocol analyses as well as several meta-analyses report a benefit of PFO closure. In our opinion, PFO
closure is underutilized and the results of the three RCTs are not adequately reflected in the current guidelines.
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Case vignettes
A 37-year-old nurse and mother of two teenage boys suffered from
migraine for many years. She was admitted to the hospital with a
stroke that left her with permanent aphasia. It took 2 years before
her patent foramen ovale (PFO) was looked for and closed, which
improved her migraine.
It was the evening of 18 December 2005. Ariel Sharon, prime
minister of Israel, was on his way home, when he suddenly had dif-
ficulties articulating. He was diagnosed with a transient ischaemic at-
tack (TIA) and recovered quickly. A plausible reason for his TIAwas
identified: a PFO. Hewas slated to undergo percutaneous PFO clos-
ure after the Holidays on 5 January 2006. Until the procedure, the
primeminister was treated with low-molecular-weight heparin. Tra-
gically, the day before the scheduled procedure he collapsed at
home and was hospitalized. Haemorrhagic stroke was the diagnosis.
He never recovered from this incident and remained in a coma for 8
years until his death in January 2014.
The two patients are exemplary for PFO-associated events in sev-
eral regards: first, a causative relation between a PFO and a particu-
lar event is always hypothetical. Secondly, PFO-associated events
can have devastating sequelae. Thirdly, anticoagulation is the only
valuable alternative to PFO closure, but bears a relevant lifetime
risk of bleeding. And last but not least, migraine is associated with
PFO and PFO closure formigraine includes the potential of preventing
stroke.
Patent foramen ovale closure, still
a wallflower
Interventional cardiology has to weigh the benefits against the risks
of a procedure in a particular patient. The more effective and the
safer an intervention, the higher the adoption in clinical practice. Pa-
tent foramen ovale closure is the simplest intervention in interven-
tional cardiology. A single operator can safely and virtually painlessly
perform the procedure using local groin anaesthesia. It takes
15 min and the patient can leave the hospital a few hours later
without any physical restrictions. Nonetheless, many still question
that the safety of PFO closure be outweighed by its effectiveness
as a preventive intervention.
On a more global perspective, the annual incidence of stroke in
the western world (Western Europe and North America) amounts
to 1.6 million; 1% of these strokes are recurrent strokes and 15%
of these recurrent strokes are presumably caused by a PFO.1 If all
PFOs were closed for secondary prevention (240 000 PFO closures
that is), 1150 strokes could theoretically be prevented annually
when compared with a scenario where all patients with recurrent
strokes and PFO were treated medically (assuming an 80% efficacy
of PFO closure with a 60% relative risk reduction when compared
with medical therapy).
The benefit may be even greater when looking at the data from a
randomized controlled trial (RCT)2: only 25 PFOs needed to be
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closed for secondary prevention in order to avoid one stroke within
5 years. In a population at an average age of 60 years, only about five
PFOs need to be closed to prevent one stroke; less with PFO clos-
ure at a younger age.
Current evidence
In addition to numerous registry analyses and non-randomized
comparisons, three RCTs on PFO closure vs. medical therapy for
secondary prevention of stroke have been published. TheCLOSURE-1
trial (Evaluation of the STARFlex Septal Closure System in Patients
with a Stroke and/or Transient Ischemic Attack due to Presumed
Paradoxical Embolism through a Patent Foramen Ovale)3 randomized
909 patients to either PFO closure (using the no longer available
STARFlex device from NMT Medical, Boston, MA, USA) or medical
therapy (vitamin K antagonist or acetylsalicylic acid). The PC trial
(Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Em-
bolism)4 enrolled 414 patients and the RESPECT trial (Randomized
Evaluation of Recurrent StrokeComparing PFOClosure to Established
Current Standard of Care Treatment)2 enrolled 980 patients to under-
go PFO closure using the Amplatzer PFO Occluder (St Jude Medical,
Plymouth, MN, USA) or medical therapy (vitamin K antagonist or anti-
platelet therapy). Mean follow-up ranged from 2 to 4 years.
Safety of patent foramen ovale closure
Safety of PFO closure emerges from the non-randomized and ran-
domized trials, equally. Neither in the PC nor in the RESPECT trial
were adverse events more common in the closure group than in the
medical group (PC: 21 vs. 18%, P ¼ 0.37; RESPECT: 23 vs. 22%, P ¼
0.65). Importantly, none of the adverse events resulted in either
death or permanent disability.
Patent foramen ovale closure is associated with an increased inci-
dence of atrial fibrillation. In the PC trial, the incidence of atrial fib-
rillation after PFO closure was 2.9% in the device group vs. 1.0% in
the medical group (P ¼ 0.17). In the CLOSURE-1 trial using the
obsolete STARFlex device, the difference was more marked and
significant (5.7 vs. 0.7%, P . 0.001). The three RCTs were likely
underpowered for the occurrence of adverse events. Given the
three- and eight-fold increases, respectively, in the incidence of atrial
fibrillation, a potential harm of the intervention cannot be excluded.
It seems, however, that device choice plays an important role in the
occurrence of atrial fibrillation and it is furthermore important to
note that two-thirds of these events in the device group happened
within the first 2 weeks and only a few patients needed treatment
for conversion or oral anticoagulation. This represents therefore a
relatively harmless form of atrial fibrillation regarding stroke risk
compared with the chronic forms in the elderly patients.
To reduce the small potential risk of device-induced atrial fibrilla-
tion, data suggest to use Amplatzer(-like) devices as a first choice.
The difference in the safety profile of different PFO closure de-
vices was confirmed in a randomized study comparing the Amplat-
zer, STARFlex, and Helex (W.L. Gore & Associates, Inc., Flagstaff,
AZ, USA) devices.5 Procedural complications (device embolization,
air embolism, or cardiac tamponade) happened most frequently
with the use of the Helex device, whereas the STARFlex device
had the worst safety profile during follow-up (atrial fibrillation in
12.3% and device thrombus in 5.0%).
Efficacy of patent foramen ovale closure
Rates of complete PFO closure were .95 and .93%, respectively,
in the Amplatzer trials, but only 86% in the CLOSURE-1 trial. Clos-
ure rates matter since residual shunts have been associated with
more recurrent events.6 Residual shunts can be successfully treated
with a second procedure (Figure 1).7 Yet, re-closure with a second
device is rarely performed, presumably also due to a prevailing
overly complex approach to PFO closure, implying general anaes-
thesia and peri-procedural guidance with transoesophageal echo-
cardiography (TOE).
Underpowered trials and meta-analyses
All three RCTs are statistically not significant on their own with re-
gard to the intention-to-treat analyses. Notwithstanding, all three
RCTs point into the same direction with numerically less events
in the PFO closure arm. In CLOSURE-1, the composite endpoint
of stroke, TIA, death within 30 days, or death due to neurological
causes from day 31 to 2 years occurred over 2 years in 5.5% of pa-
tients in the closure arm and 6.8% of patients in the medical arm
[hazard ratio (HR) 0.78; 95% CI 0.45–1.35; P ¼ 0.37]. In the PC trial,
the composite endpoint of death, non-fatal stroke, TIA, or periph-
eral embolism within 4 years occurred in 3.4 and 5.2% in the PFO
closure and the medical arm, respectively (HR 0.63; 95% CI 0.24–
1.62; P ¼ 0.34). In the RESPECT trial, 0.66 vs. 1.38 recurrent strokes
per 100 patient-years occurred in the respective groups (HR 0.49;
95% CI 0.22–1.11; P ¼ 0.08). This indicates that the three RCTs
were most likely underpowered regarding patient number or
follow-up duration. The PC trial assumed the incidence of recurrent
events in the medical therapy group to be 3% per year, when in fact
it was roughly 1% per year. In the CLOSURE-1 trial, the incidence of
the primary endpoint at 2 years was assumed to be 6% for the med-
ical therapy arm and 3% in the PFO closure arm. After slow recruit-
ment and when additional data on the incidence of recurrent
strokes became available, the statistical analysis was revised during
the conduction of the trial and the projected incidence in the device
arm was reduced to 2% (thereby curtailing the sample size from
1600 to 800 patients). The observed incidence in the trial, however,
was only 3.4% in the medical arm and 2.8% in the device arm. It were
therefore mostly the patients in the medical treatment arm who
performed better than assumed.
One possible way to overcome the limitation of underpowered
trials is the analysis per treatment, which was significantly in favour
of PFO closure in the RESPECT trial.2 Another is to perform a
meta-analysis. Several meta-analyses confirmed the superiority of
PFO closure over medical therapy (Figure 2).8,9 Rengifo-Moreno
et al.8 found a significant relative risk reduction for TIA or stroke
of 41% (95% CI 0.36–0.97, P ¼ 0.04) and for death, neurological
events, and peripheral embolism of 33% (95% CI 0.44–1.00, P ¼
0.05) in favour of PFO closure. A device-specific analysis of all avail-
able RCTs reported a significant 61% relative risk reduction, when
only randomized trials with the Amplatzer device were included
(95% CI 0.17–0.84). Including the STARFlex or the Helex devices
blunts the benefit somewhat.10 The authors of the latter meta-
analysis further calculated the probability of each treatment to be
the best to prevent stroke. It was 77% for the Amplatzer device
and only 0.4% for medical therapy.
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The two randomized Amplatzer trials (PC4 and RESPECT2)
showed some strong trends, all in favour of PFO closure. In the
PC trial, when using the contemporary stroke definition of the RE-
SPECT trial, only one stroke occurred in the closure arm in contrast
to seven strokes in the medical arm (HR 0.14, 95% CI 0.02–1.17,
P ¼ 0.07). This corroborates the results of the RESPECT trial (HR
0.49, 95% CI 0.22–1.11, P ¼ 0.08). In the RESPECT trial, the risk re-
duction was even more pronounced when the composite of stroke
and cardiovascular death was looked at (HR 0.17, 95%CI 0.02–1.47,
P ¼ 0.07).
Recurrent strokes after PFO closure occurred exclusively early
after PFO closure in the PC trial. No temporal pattern could be
identified in the medical group where recurrent strokes occurred
at random throughout the study period. Longer follow-up will
show whether the curves keep diverging. Importantly, recurrent
strokes were moderate to massive in the majority of patients in
the medical treatment group, whereas only in a minority of patients
in the PFO closure group (63 vs. 14%, P ¼ 0.06). This suggests that
recurrent strokes may be less severe after PFO closure than after
medical therapy.
Per-protocol and as-treated analyses
Intention-to-treat analyses come with their own limitations in med-
ical device trials: for instance, two patients suffered a TIA in the
CLOSURE-1 trial while awaiting PFO closure. In the intention-to-
treat analysis, these events are counted as events in spite of PFO
closure.
The RESPECT trial reported a trend favouring PFO closure in the
intention-to-treat analysis (9 vs. 16 events with a HR with closure of
0.49, 95% CI 0.22–1.11, P ¼ 0.08). Patent foramen ovale closure
was significantly better than medical therapy in the per-protocol
(6 vs. 14 events, HR 0.37, 95% CI 0.14–0.96, P ¼ 0.03) and the
as-treated analyses (5 vs. 16 events, HR 0.39, 95% CI 0.10–0.75,
P ¼ 0.007).
Subgroup analyses and very long-term follow-up
In the subgroup analyses of the RESPECT trial, therewas a significant
benefit of PFO closure when compared with patients treated med-
ically with acetylsalicylic acid alone (1.4 vs. 3.6%, HR 0.34, 95% CI
0.12–0.94, P ¼ 0.03). Vitamin K antagonists performed as well as
PFO closure (3.0 vs. 2.5%, HR 1.14, 95% CI 0.26–5.1, P ¼ 0.86).
Therefore, the only alternative to PFO closure is lifelong oral antic-
oagulation with its accruing and ever-increasing risk of bleeding.
Having this in mind and the fact that strokes occurred throughout
the study period with medical therapy, one can expect an accumu-
lating benefit with PFO closure with growing follow-up. This was in-
deed shown in an observational study of 308 patients with .10
years of follow-up11: a lower risk for stroke was found for patients
Figure 1 Second device for residual leak at follow-up of patent foramen ovale closure. A 70-year-old man with stroke was found on transoe-
sophageal echocardiography (TOE) to have a significant residual leak 6 months after patent foramen ovale closure with a 30 mm Cribriform Am-
platzer Occluder (A). The residual shunt was angiographically confirmed (B) and a second device (18 mm Amplatzer PFO Occluder) was
implanted (C) with complete closure documented by TOE 6 months later (D).
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who underwent PFO closure when compared with medical therapy.
Even more impressive, a mortality benefit during years after PFO
closure when compared with years before or without PFO closure
was observed. Patent foramen ovale closure resulted in a significant
64% relative risk reduction for death (Figure 3). Moreover, a
propensity-matched analysis of about 200 patients was performed.
It showed a significant reduction in the composite endpoint of
stroke, TIA, or peripheral embolism in favour of PFO closure.
Patients with a significant right-to-left shunt or an atrial septal an-
eurysm at TOE not only have a more dangerous PFO, but they were
also identified as a subgroup of patients to have a significant benefit
of PFO closure in the RESPECT trial with a risk reduction of 82 and
81%, respectively (HR ¼ 0.18, 95% CI 0.04–0.81, P ¼ 0.01 with
P-value for interaction 0.07 and HR ¼ 0.19, 95% CI 0.04–0.87,
P ¼ 0.02 with P-value for interaction 0.10).
In summary, evidence suggests that the PFO is less dangerous re-
garding repeat cerebral events than suggested in the neurological lit-
erature of the 1980s. This has led to underpowered trials and the
fact that strictly evidence-based medicine does not recommend
PFO closure over medical therapy. The numerous sub-analyses or
meta-analyses, however, invariably favour PFO closure. Although
statistically not as powerful as the intention-to-treat analysis of a
RCT, the additional analyses all point into the same direction and
should not be ignored. Moreover, a single small percutaneous inter-
vention appears more attractive than lifelong blood thinners even in
case of egality rather than superiority.
Current guidelines
In the most recent American guidelines,12 PFO closure without evi-
dence for deep venous thrombosis is not supported and in the pres-
ence of deep venous thrombosis only received a class IIb/level of
evidence C recommendation. The European Stroke Organisation
guidelines13 only consider PFO closure in patients with cryptogenic
stroke and a high-risk PFO and were written in 2008 when the
current evidence was yet not available. Therefore, the current evi-
dence needs to be more adequately reflected in the current guide-
lines (Table 1).
So far, guidelines only consider PFO closure in the setting of a
‘cryptogenic’ stroke. ‘Cryptogenic stroke’ is a misnomer, since it ex-
cludes PFO as an established cause of stroke in contrast to atrial
fibrillation or carotid atherosclerosis. The presence of a PFO in pa-
tients with stroke/TIA should prompt PFO closure to eliminate at
least one of the potential stroke causes. Patent foramen ovale clos-
ure should be withheld only if another indication for ongoing oral
Figure 2 Relative risk reduction in different meta-analyses.8,9 Superiority of patent foramen ovale closure over medical therapy was confirmed
with relative risk reduction for recurrent stroke/transient ischaemic attack of 33–58%. Left: superiority of patent foramen ovale closure in the
intention-to-treat analyses (hazard ratio 0.54–0.67). Middle: superiority of patent foramen ovale closure in the per-protocol analyses (hazard ratio
0.48–0.62). Right: superiority of patent foramen ovale closure in the as-treated analyses (hazard ratio 0.42–0.61). CI, confidence interval.
Figure 3 Ten-year outcome of patients after patent foramen
ovale (PFO) closure (patent foramen ovale with the device) com-
pared with those on medical treatment (patent foramen ovale
without the device) in terms of yearly risk of death, stroke, or tran-
sient ischaemic attack. There is a significant survival benefit with
patent foramen ovale closure.11
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anticoagulation (e.g. mechanical heart valve) or a contraindications
exist.
Time for patent foramen ovale
closure for primary prevention?
Bearing in mind a small excess of atrial fibrillation caused by PFO
closure, primary prevention should address high-risk patients.
Patent foramen ovale properties
As shown in multiple studies, the probability that a PFO is the cause
of an embolic event is higher in patients with a ‘dangerous’ PFO
(PFO associated with an atrial septal aneurysm, an Eustachian valve
or Chiari network, or a large spontaneous shunt)—therefore, ana-
tomical findings (particularly on TOE) help to define a high-risk
population.14 Younger and otherwise healthy patients with a PFO
have a higher relative risk of the PFO being responsible for an em-
bolic event, although the absolute PFO risk increases with age and
disease burden (more thrombi in the venous system).
Patent foramen ovale and migraine
Migraine patients may experience collateral benefit of PFO closure
in the form of prevention of paradoxical embolism in addition to
possible migraine alleviation. The 37-year-old nurse suffered from
migraine before experiencing a devastating embolic stroke. If her mi-
graine had led to screening for a PFO with the intention to close it
for the potential benefit on migraine, the subsequent catastrophic
stroke would likely have been avoided. Evidence confirms an asso-
ciation of migraine and PFO. In an observational study on.600 con-
secutive PFO closures,15 one-fourth of patients suffered from
concomitant migraine, whereof 64% suffered from severe migraine
with aura. After PFO closure, migraine was cured in 34% and im-
proved in 85% of these patients. Patients suffering from migraine
with aura had a particularly favourable improvement of their symp-
toms with 39% of these patients being cured from their migraine
after PFO closure. Therefore, patients suffering from migraine
have a high chance to experience improvement of their symptoms
by PFO closure—as a ‘collateral benefit’ they will also be protected
from paradoxical embolism. Theymay therefore be a target for PFO
closure for primary stroke prevention.
Screening for patent foramen ovale
Similar to patients with migraine, other conditions are associated
with PFO and have a worthwhile chance to improve after PFO clos-
ure. Besides, persons with high-risk activities and persons at high risk
for venous thrombosis, the prerequisite of paradoxical embolism
could be considered for primary preventive PFO closure. A simple
screening transthoracic echocardiography (TTE) bubble study may
miss small PFOs, but likely identifies persons with a ‘dangerous’ PFO.
They represent 5% of the population. Table 2 lists conditions and
people that consider reasonable subjects to undergo such a screen-
ing test.16
Possible strategies to support patent
foramen ovale closure for primary
prevention
It must be stressed that there are currently no data supporting PFO
closure for primary prevention. However, it seems reasonable to
give it due thought at least for PFOs with aggravating attributes in
light of the devastating consequences a PFO-associated event can
cause.
Given the slow recruitment and the long follow-up that was
needed to complete the RCTs on PFO closure for secondary stroke
prevention, it is unlikely that a RCT on primary prevention will be
conducted in the near future. Nation-wide or multinational regis-
tries on primary prevention may therefore add valuable evidence.
Also, company-initiated worldwide registries would be welcomed.
Screening of young people with a life expectancy of.50 years for
a PFO has to be considered, as only two PFOs need to be closed to
avoid one stroke, assuming a comparable risk reduction for primary
prevention in high-risk patients as for secondary prevention.
Closing all PFOs for secondary prevention and even more so if
primary prevention in a subgroup of patients was considered, the fi-
nancial burden for the health-care system would be considerable.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Patients with an ischaemic stroke/TIA and the presence of a PFO
AHA/ASA Guidelines12 ESO Guidelines13 Suggested guidelines
Without DVT data do not
support PFO closure (class III,
level A)
With high-risk PFO (ASA, EV, and
CN) PFO closure is considered
(class IV)
PFO closure is recommended, even in the presence of other potential
causes of stroke.
With DVT PFO closure might
be considered
In patients with more than one
stroke PFO closure is considered
(class IV)
In patients with contraindication to PFO closure, oral anticoagulation is
recommended
PFO closure for primary prevention can be considered in patients at high
risk for paradoxical embolism due to tendency for venous
thrombosis, vocational or recreational activities fostering right to left
shunts, or aggravating PFO attributes (ASA, EV, CN, etc.), or those
who can expect a collateral benefit (e.g. patients suffering from
migraine)
For PFO closure, Amplatzer(-like) devices should be preferably used
TIA, transient ischaemic attack; ASA, atrial septal aneurysm; CN, Chiari network; DVT, deep venous thrombus; EV, Eustachian valve; PFO, patent foramen ovale.
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On the other hand, prevention pays back at least in part by avoiding
costly clinical events. A more pro-active role of health-care author-
ities with regard to PFO closure seems therefore justified. In some
individuals, tremendous suffering can be avoided.
Conclusions
Stroke is among the most devastating diseases for patients and their
families. It can cause loss of self-determination and independence. In
a society where life expectancy of the general population is steadily
increasing, it is the role of physicians to take every effort not only to
prolong life, but also to preserve quality of life.
The role of cardiology is crucial to achieve this goal. Cardiology
has to offer many therapies that prolong life and increase quality
of life for patients. Patent foramen ovale closure is one of them. It
is a simple, safe, and effective treatment that can make a difference
for patients. It is a once-in-a-lifetime intervention and has therefore
been referred to as a mechanical vaccination against some forms of
stroke, myocardial infarction, and other systemic embolism.17
The current evidence does not seem to be sufficiently reflected in
the European and American guidelines and a more pro-active role in
PFO closure for secondary prevention and for high-risk patients ap-
pears justified. A simple screening test, perhaps building on ear-lobe
oximetry,18 is direly needed.
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Table 2 Conditions and people justifying screening for
PFO
- Conditions associated with PFO
† Migraine
† Sleep apnoea
† High altitude pulmonary oedema
† Platypnoea orthodeoxia or exercise desaturation
- High-risk activities
† Weight lifters, brass musicians, glass blowers, tile setters
(frequent Valsalva manoeuvres)
† Frequent flyers, pilots (high-risk for deep venous thrombosis)
† Deep sea divers, military pilots, astronauts (risk of venous gas
formation or microcavitations)
- Pacemaker- and internal cardioverter-defibrillator carriers (clots on
cables)16
PFO, patent foramen ovale.
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